Post Title
LOREM IPSUM DOLOR SIT AMET

14 Mar: aptaTargets announces completion of enrollment in the Phase I study of ApTOLL in healthy volunteers

aTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.

13 Jun: First Patient in the ApTOLL-FIH-01 trial: a Phase I trial in healthy volunteers

AptaTargets has started the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.